NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

Rhea-AI Summary

NEXGEL (NASDAQ:NXGL) announced financing of $1.797 million related to a potential acquisition targeted to close in the first quarter of 2026. The transaction is subject to mutual due diligence and other conditions, and funds will be returned to the investor if the acquisition is not consummated. The investor may provide a potential additional $14.869 million pending completion of full due diligence. Palladium Capital Group acted as placement agent. The company said it will provide further details to shareholders during Q1 2026.

Positive

• Committed financing of $1.797 million
• Potential follow-on investment of $14.869 million
• Acquisition targeted to close in Q1 2026

Negative

• Transaction subject to mutual due diligence and other conditions
• Funds refundable to investor if transaction is not consummated

News Market Reaction – NXGL

+2.33%

3 alerts

+2.33% News Effect

+6.4% Peak Tracked

+$276K Valuation Impact

$12M Market Cap

1.4x Rel. Volume

On the day this news was published, NXGL gained 2.33%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $276K to the company's valuation, bringing the market cap to $12M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Acquisition financing: $1.797 million Additional investment: $14.869 million Current share price: $1.29 +1 more

4 metrics

Acquisition financing $1.797 million Committed financing tied to potential acquisition, refundable if not consummated

Additional investment $14.869 million Potential incremental investment related to the acquisition, post-due diligence

Current share price $1.29 Pre-news close vs 52-week range of $1.18–$3.66

Market cap $10,341,779 Equity value prior to acquisition financing announcement

Market Reality Check

Price: $1.15 Vol: Volume 39,528 is in line ...

normal vol

$1.15 Last Close

Volume Volume 39,528 is in line with 20-day average of 39,627. normal

Technical Shares at $1.29 are trading below the 200-day MA of $2.21, near the 52-week low of $1.18 and well under the $3.66 high.

Peers on Argus

NXGL was modestly higher pre-news with a 1.57% 24h gain while only one close pee...

1 Up

NXGL was modestly higher pre-news with a 1.57% 24h gain while only one close peer, HBIO, appeared on momentum scanners, moving up 15.54% without same-day deal news. Other peers showed mixed price changes, pointing to a stock-specific rather than broad sector move.

Previous Acquisition Reports

1 past event · Latest: May 16 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
May 16	Acquisition announcement	Positive	+2.7%	Acquisition of Silly George beauty brand with added revenue and synergies.

Pattern Detected

The company’s prior acquisition announcement generated a modest positive price reaction, suggesting deal news has historically been viewed constructively.

Recent Company History

Over the past 18 months, NEXGEL has used acquisitions alongside spin-offs and financing to shape its portfolio. A prior acquisition on May 16, 2024 added the Silly George beauty brand and drove a 2.74% one-day gain as investors reacted to added revenue and strategic synergies. Today’s financing tied to a potential acquisition in Q1 2026 fits this pattern of using targeted deals to expand consumer and healthcare offerings while leveraging existing hydrogel capabilities.

Historical Comparison

+2.7% avg move · In the past, NXGL’s only recorded acquisition headline on May 16, 2024 led to a 2.74% move. This new...

acquisition

+2.7%

Average Historical Move acquisition

In the past, NXGL’s only recorded acquisition headline on May 16, 2024 led to a 2.74% move. This new acquisition-related financing update continues the use of deals as a strategic lever, with prior data suggesting moderate but positive sensitivity to such announcements.

Acquisition strategy has evolved from buying a revenue-generating beauty brand toward structuring investor-backed financing for a future acquisition targeted for Q1 2026.

Market Pulse Summary

This announcement outlines a committed $1.797 million financing, plus a potential additional $14.869...

Analysis

This announcement outlines a committed $1.797 million financing, plus a potential additional $14.869 million, earmarked for a targeted acquisition in the first quarter of 2026, contingent on due diligence. It continues NEXGEL’s pattern of using acquisitions to expand its healthcare and consumer footprint. Investors may track upcoming Form 8-K disclosures, deal terms, and how any acquired assets complement the company’s hydrogel-based product strategy and prior Silly George acquisition.

Key Terms

due diligence, placement agent, form 8-k

3 terms

due diligence financial

"The potential acquisition is subject to the completion of due diligence by both NEXGEL"

Due diligence is the careful investigation and analysis someone conducts before making a decision, such as investing money or entering into an agreement. It’s like researching thoroughly before buying a used car to ensure it’s in good condition; this helps prevent surprises and makes informed choices. For investors, due diligence reduces risk by verifying details and understanding what they’re getting into.

placement agent financial

"Palladium Capital Group, LLC acted as the placement agent on the transaction."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

form 8-k regulatory

"described in the Current Report on Form 8-K filed with the Securities and Exchange"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. Not financial advice.

LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated.

“After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions,” said Adam Levy, CEO of NEXGEL. “We have identified assets to acquire with an up-front commitment from an investor in the amount of $1.797 million and a potential additional investment of $14.869 million relating to the acquisition, pending the completion of full due diligence by both parties and subject to other conditions. We expect to provide shareholders with further information on the acquisition during the first quarter of 2026.”

Palladium Capital Group, LLC acted as the placement agent on the transaction.

The financing transaction is more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026.

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal^®, Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com

FAQ

What financing did NEXGEL (NXGL) announce on February 10, 2026?

NEXGEL announced financing of $1.797 million tied to a potential acquisition. According to the company, the financing is for a targeted Q1 2026 acquisition and may include a potential additional $14.869 million pending due diligence.

When does NEXGEL expect the acquisition related to the NXGL financing to close?

NEXGEL expects the acquisition to target closing in the first quarter of 2026. According to the company, completion remains subject to mutual due diligence and other customary conditions before closing can occur.

Is the $1.797 million financing for NXGL refundable if the acquisition falls through?

Yes, the funds will be returned to the investor if the transaction is not consummated. According to the company, the financing is conditional and refundable pending completion of due diligence by both parties.

Who acted as placement agent for NEXGEL's February 10, 2026 financing?

Palladium Capital Group served as the placement agent on the transaction. According to the company, Palladium Capital Group, LLC facilitated the placement related to the potential acquisition financing.

How large could the total investor commitment be for the NXGL acquisition?

The initial commitment is $1.797 million with a potential additional $14.869 million. According to the company, the larger commitment depends on completion of full due diligence and satisfaction of other conditions.